STOCK TITAN

[Form 4] Iridex Corp Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Iridex Corp (IRIX) insider purchase reported: Chief Financial Officer Romeo R. Dizon acquired 1,000 shares of Iridex common stock on 09/05/2025 at $1.35 per share, increasing his beneficial ownership to 55,750 shares. The Form 4 was signed by an attorney-in-fact on 09/08/2025. No derivative transactions or additional details were reported.

Acquisto da parte di un dirigente di Iridex Corp (IRIX): Il Chief Financial Officer Romeo R. Dizon ha acquistato 1.000 azioni ordinarie di Iridex il 05/09/2025 al prezzo di $1,35 per azione, portando la sua partecipazione beneficiaria a 55.750 azioni. Il modulo Form 4 è stato firmato per procura il 08/09/2025. Non sono state segnalate transazioni su derivati né ulteriori dettagli.

Compra por parte de un insider de Iridex Corp (IRIX): El director financiero Romeo R. Dizon adquirió 1.000 acciones ordinarias de Iridex el 05/09/2025 a $1,35 por acción, elevando su participación beneficiaria a 55.750 acciones. El Formulario 4 fue firmado por apoderado el 08/09/2025. No se informaron operaciones con derivados ni más detalles.

Iridex Corp(IRIX) 임원 매입 신고: 최고재무책임자(CFO) 로미오 R. 디존(Romeo R. Dizon)이 2025-09-05에 Iridex 보통주 1,000주를 주당 $1.35에 매수하여 실소유 지분이 55,750주로 늘어났습니다. Form 4는 2025-09-08에 대리인이 서명했습니다. 파생상품 거래나 추가 내역은 보고되지 않았습니다.

Achat d'initié chez Iridex Corp (IRIX) signalé : Le directeur financier Romeo R. Dizon a acquis 1 000 actions ordinaires d'Iridex le 05/09/2025 au prix de 1,35 $ par action, portant sa participation bénéficiaire à 55 750 actions. Le formulaire 4 a été signé par un mandataire le 08/09/2025. Aucune opération sur produits dérivés ni détail supplémentaire n'a été déclaré.

Insider-Kauf bei Iridex Corp (IRIX) gemeldet: Chief Financial Officer Romeo R. Dizon erwarb am 05.09.2025 1.000 Iridex-Stammaktien zu je $1,35 und erhöhte damit seinen wirtschaftlichen Besitz auf 55.750 Aktien. Das Formular Form 4 wurde am 08.09.2025 von einem Bevollmächtigten unterzeichnet. Es wurden keine Derivatgeschäfte oder weiteren Details gemeldet.

Positive
  • Insider purchase disclosed: CFO Romeo R. Dizon acquired 1,000 shares at $1.35 per share on 09/05/2025
  • Increased beneficial ownership: Ownership rose to 55,750 shares, demonstrating insider engagement
  • Clean filing: Transaction reported on Form 4 with signature (attorney-in-fact) and no apparent errors
Negative
  • None.

Insights

TL;DR: CFO bought 1,000 IRIX shares at $1.35, a small insider purchase that signals limited direct conviction.

This Form 4 documents a straightforward purchase by the company's Chief Financial Officer increasing beneficial ownership to 55,750 shares. The transaction is non-derivative, executed on 09/05/2025 at $1.35 per share. Given the modest size relative to typical company float and absence of other filings or changes, the transaction appears routine rather than material.

TL;DR: Insiders reporting purchases are governance-positive, but this single small buy is not materially impactful.

The filing is properly completed, identifies the reporting person as CFO, and is signed via attorney-in-fact. There are no amendments, derivative holdings, or plan-related disclosures noted. Procedurally clean filing; no governance concerns evident from the disclosed information alone.

Acquisto da parte di un dirigente di Iridex Corp (IRIX): Il Chief Financial Officer Romeo R. Dizon ha acquistato 1.000 azioni ordinarie di Iridex il 05/09/2025 al prezzo di $1,35 per azione, portando la sua partecipazione beneficiaria a 55.750 azioni. Il modulo Form 4 è stato firmato per procura il 08/09/2025. Non sono state segnalate transazioni su derivati né ulteriori dettagli.

Compra por parte de un insider de Iridex Corp (IRIX): El director financiero Romeo R. Dizon adquirió 1.000 acciones ordinarias de Iridex el 05/09/2025 a $1,35 por acción, elevando su participación beneficiaria a 55.750 acciones. El Formulario 4 fue firmado por apoderado el 08/09/2025. No se informaron operaciones con derivados ni más detalles.

Iridex Corp(IRIX) 임원 매입 신고: 최고재무책임자(CFO) 로미오 R. 디존(Romeo R. Dizon)이 2025-09-05에 Iridex 보통주 1,000주를 주당 $1.35에 매수하여 실소유 지분이 55,750주로 늘어났습니다. Form 4는 2025-09-08에 대리인이 서명했습니다. 파생상품 거래나 추가 내역은 보고되지 않았습니다.

Achat d'initié chez Iridex Corp (IRIX) signalé : Le directeur financier Romeo R. Dizon a acquis 1 000 actions ordinaires d'Iridex le 05/09/2025 au prix de 1,35 $ par action, portant sa participation bénéficiaire à 55 750 actions. Le formulaire 4 a été signé par un mandataire le 08/09/2025. Aucune opération sur produits dérivés ni détail supplémentaire n'a été déclaré.

Insider-Kauf bei Iridex Corp (IRIX) gemeldet: Chief Financial Officer Romeo R. Dizon erwarb am 05.09.2025 1.000 Iridex-Stammaktien zu je $1,35 und erhöhte damit seinen wirtschaftlichen Besitz auf 55.750 Aktien. Das Formular Form 4 wurde am 08.09.2025 von einem Bevollmächtigten unterzeichnet. Es wurden keine Derivatgeschäfte oder weiteren Details gemeldet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Dizon Romeo R

(Last) (First) (Middle)
1212 TERRA BELLA AVENUE

(Street)
MOUNTAIN VIEW CA 94043

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
IRIDEX CORP [ IRIX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
09/05/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 09/05/2025 P 1,000 A $1.35 55,750 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
/s/ Nilo De Castro, Attorney-in-fact for Romeo R. Dizon 09/08/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did IRIX insider Romeo R. Dizon report?

The CFO reported acquiring 1,000 shares of Iridex common stock on 09/05/2025 at $1.35 per share.

How many IRIX shares does Romeo R. Dizon beneficially own after the purchase?

Following the reported transaction, he beneficially owns 55,750 shares.

Was the Form 4 for IRIX amended or signed late?

The form shows the transaction date as 09/05/2025 and the filing was signed by an attorney-in-fact on 09/08/2025; no amendment date is indicated.

Did the Form 4 report any derivative or option transactions for IRIX?

No. Table II (derivative securities) contains no reported transactions or holdings.

What is the reporting relationship of Romeo R. Dizon to IRIX?

He is reported as an Officer (Chief Financial Officer) and the form indicates the officer box is checked.
Iridex

NASDAQ:IRIX

IRIX Rankings

IRIX Latest News

IRIX Latest SEC Filings

IRIX Stock Data

21.75M
12.23M
27.64%
15.83%
1.6%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States
MOUNTAIN VIEW